CeriBell, Inc.(CBLL) - 2024 Q3 - Quarterly Report

Business Performance - Total revenue for the three months ended September 30, 2024, was $17,195 million, a 48$11,611 million in the same period of 2023[159]. - Product revenue for the three months ended September 30, 2024, increased by $4,557 million, or 52$1,027 million, or 36%, compared to the same period in 2023[163]. - Gross profit for the three months ended September 30, 2024, was $15,011 million, a 54$9,726 million in the same period of 2023[166]. - Total revenue for the nine months ended September 30, 2024, was $46,910 million, a 46$32,094 million in the same period of 2023[161]. Financial Position - The company reported an accumulated deficit of $154.4 million as of September 30, 2024, with cash and cash equivalents of$14.1 million[140]. - The company has received aggregate gross proceeds of $151.0 million from sales of common stock and$35.0 million from term loans since inception[140]. - Net cash used in operating activities for the nine months ended September 30, 2024, was $25.068 million, compared to$22.484 million for the same period in 2023, reflecting an increase in net loss from $21.2 million to$27.9 million[174][176]. - Principal payments required on long-term debt outstanding as of September 30, 2024, were $20.0 million[179]. - Estimated contractual obligations for operating lease payments as of September 30, 2024, were$2.8 million due within 28 months[179]. Operating Expenses - Total operating expenses for the three months ended September 30, 2024, were $24,948 million, an increase of 48$16,890 million in the same period of 2023[159]. - General and administrative expenses increased by $4,039 million, or 81$1,087 million, or 47%, for the three months ended September 30, 2024, compared to the same period in 2023[168]. - Sales and marketing expenses are anticipated to rise as the company increases its sales organization and market penetration in the U.S.[153]. Cash Flow - Net cash used in investing activities remained consistent at $1.1 million for both the nine months ended September 30, 2024 and 2023, primarily for equipment purchases[177]. - Net cash provided by financing activities increased significantly to$5.788 million in the nine months ended September 30, 2024, compared to $0.644 million in 2023, driven by$7.6 million in net proceeds from debt issuance[178]. Product and Market Development - As of September 30, 2024, the Ceribell System has been adopted by over 500 active accounts and has been used to care for over 100,000 patients[135]. - The Ceribell System aims to become the standard of care for seizure detection in approximately 5,800 acute care facilities in the U.S.[137]. - The Ceribell System integrates AI-powered algorithms for real-time assessment of seizure activity, enhancing patient care in acute settings[136]. - Revenue is generated from two sources: product revenue from disposable headbands and subscription revenue from monthly fees for the Clarity system[145]. - The company expects revenue fluctuations due to the success of its sales force in extending adoption of the Ceribell System and seasonal factors affecting patient volume[146]. - The company has dual sources for major components of the Ceribell headband, ensuring supply chain resilience[138]. Other Financial Metrics - Net loss for the three months ended September 30, 2024, was $(10,417) million, a 48$(7,054) million in the same period of 2023[159]. - Interest and other income (expense), net decreased by $590 million for the three months ended September 30, 2024, compared to the same period in 2023[173]. - The increase in operating assets for the nine months ended September 30, 2024, was$3.6 million, attributed to inventory purchases and accounts receivable due to increased sales[175]. - The net decrease in operating liabilities for the nine months ended September 30, 2024, was $1.5 million, primarily due to timing of payments[175]. - The company reported a net increase in operating assets of$4.9 million for the nine months ended September 30, 2023, indicating a similar trend in sales growth[176]. Research and Development - Research and development expenses are expected to increase as the company continues to improve its algorithm and expand clinical applications[151]. - The company has made no material changes to its significant accounting policies and estimates as described in the Prospectus[181].